PT  - JOURNAL ARTICLE
AU  - Prattay Guha Sarkar
AU  - Amit Kumar
AU  - Debdutta Bandyopadhyay
TI  - CHA2DS2-VASc score on admission to predict mortality in COVID-19 patients: A meta-analysis
AID  - 10.1101/2021.06.07.21258402
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.07.21258402
4099  - http://medrxiv.org/content/early/2021/06/09/2021.06.07.21258402.short
4100  - http://medrxiv.org/content/early/2021/06/09/2021.06.07.21258402.full
AB  - Background CHA2DS2-VASc score is used in non-valvular AF patients to predict thromboembolic risk. Recent studies have tried to evaluate CHA2DS2-VASc score on admission in COVID-19 patients to predict mortality.Methods We conducted a literature search on 14 April 2021 to retrieve all published studies, pre-prints and grey literature related to the predictive power of CHA2DS2-VASc score in COVID-19 patients of admission and mortality. Screening of studies and data extraction was done by two authors independently. We used the Quality in Prognosis Studies (QUIPS) tool for the methodological quality assessment of the included studies.Results Five studies involving 5,941 patients reported the predictive value of CHA2DS2-VASc score for mortality in COVID-19 patients. The pooled sensitivity (SEN), specificity (SPE) and area under curve were 0.72 (95% CI 0.63-0.79), 0.74 (95% CI 0.67-0.81) and 0.80 (95% CI 0.76-0.83).Conclusions CHA2DS2-VASc score at admission has good predictive value for mortality in patients with COVID-19 infection and can help clinicians identify potentially severe cases early. Early initiation of effective management in these cases may help in reducing overall mortality due to COVID-19.Trial registry We prospectively registered this meta-analysis on PROSPERO database (Reg number: CRD42021248398).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialPROSPERO CRD42021248398Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=248398 Funding StatementNONEAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NOT APPLICABLEAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article. The studies included for synthesis of this meta-analysis have been mentioned in references.